3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 4 月 28 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： 中信证券股份有限公司 关于江苏金迪克生物技术股份有限公司 2024 年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏金 迪克生物技术股份有限公司（以下简称"金迪克"或"公司"或"上市公司"） 首次公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管 理办法》、《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行 持续督导职责，并出具本持续督导年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审计等内部控制制度，查阅公司 2024 年度内部控制评价报 ...

中信证券股份有限公司 中信证券股份有限公司 （二）保荐代表人 周游、赵岩 （三）现场检查人员 赵岩、李范伟 关于江苏金迪克生物技术股份有限公司 2024 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"或"保荐 人"）作为正在对江苏金迪克生物技术股份有限公司（以下简称"金迪克""公司" "上市公司"）进行持续督导工作的保荐人，对 2024 年度（以下简称"本持续督 导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐人 （四）现场检查时间 2025 年 4 月 28 日 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理和内部控制情况、信息披露 情况、公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、 募集资金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面 进行了现场检查，具体检查内容详见本报告"二、本次现场检查主要事项及意见"。 （六）现场检查手段 1 本次现场检查的手段主要包括资料查阅、访谈 ...

证券代码：688670 证券简称：金迪克 公告编号：2025-017 江苏金迪克生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 9 日 （二） 股东大会召开的地点：江苏省泰州市郁金路 12 号公司行政楼一号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 29 | | --- | --- | | 普通股股东人数 | 29 | | 2、出席会议的股东所持有的表决权数量 | 92,477,819 | | 普通股股东所持有表决权数量 | 92,477,819 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 75.0632 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 75.0632 | （四） 表决方式是否符合《公 ...

上海市锦天城律师事务所 关于江苏金迪克生物技术股份有限公司 2024 年年度股东大会的 法律意见书 锦 天 城 律 师事 务 所 ALLBRIGHT LAW OFFICES 法律意见书 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 市浦东新区银城中路501号上海中心大厦11、12层(200120) 传真:+86-21-2051-1999 +86-21-2051-1000 11, 12/F, Shanghai Tower, No. 501, Yincheng Middle Rd. Pudong New Area, Shanghai 200120, P. R. China +86-21-2051-1000 Fax: +86-21-2051-1999 www.allbrightlaw.com 上海市锦天城律师事务所 关于江苏金迪克生物技术股份有限公司 2024 年年度股东大会的 法律意见书 案号: 01G20211960 致:江苏金迪克生物技术股份有限公司 地址:上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话: 021-20511000 传真: 021-20511999 ...

文 ｜ 徐涛 梁楠 智能影像设备聚焦"便携+智能"属性，2 0 2 3年全景/运动相机全球空间近4 0 0亿，且乘风短视频、户外运动等发展浪潮，2 0 2 3 - 2 年有望以1 0%~1 5%的复合增速持续扩容。格局角度看，近年来本土厂商立足突出的产品力、持续迭代的产品矩阵已跻身全球市 场前三。供应链角度，光学+DSP/SOC为智能影像设备核心元件，成本占比超5成，同时AI等软件算法重要性持续提升。看好本 土智能影像设备产业发展，建议关注全景运动相机龙头，以及光学镜头&模组供应商。 ▍ 行业概览：智能影像设备聚焦"便携+智能"，全景/运动相机2 0 2 3年全球空间近4 0 0亿。 智能影像设备是集成计算处理能力的便携影像设备，包括全景相机、运动相机、航拍无人机、可穿戴摄影设备等，相较于传统 影像设备而言在产品形态&外观（更小巧精美等）、拍摄灵活性（更便携等）以及后期处理便捷性（快速剪辑&编辑等）等多 维度均有显著提升。2 0 1 5年前后VR浪潮到来，2 0 1 9年前后短视频平台兴起，2 0 2 2年前后户外运动需求快速成长，智能影像设 备市场受益时代浪潮而迅速增长。 ▍ 竞争格局：本土厂商已跻身全球市 ...

江苏金迪克生物技术股份有限公司 2024 年年度股东大会会议资料 证券代码：688670 证券简称：金迪克 江苏金迪克生物技术股份有限公司 2024 年年度股东大会会议资料 二〇二五年五月 1 为维护全体股东的合法权益，确保股东大会会议秩序和议事效率，保证股东 大会的顺利召开，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证监会《上市公司股东大 会规则》以及《江苏金迪克生物技术股份有限公司章程》（以下简称"《公司章程》"） 和《江苏金迪克生物技术股份有限公司股东大会议事规则》等有关规定，特制定 江苏金迪克生物技术股份有限公司（以下简称"公司"）2024 年年度股东大会会 议须知： 一、为保证股东大会的严肃性和正常秩序，切实维护与会股东（或股东代表） 的合法权益，除出席会议的股东（或股东代表）、公司董事、监事、高级管理人 员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他人员进入会场。会 议工作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、出席会议的股东及股东代理人须在会议召开前 30 分钟到达会议现场办 理签到手续 ...

Core Viewpoint - The performance of several vaccine companies in China is significantly declining in 2024 due to industry policy adjustments, decreased public willingness to vaccinate, and changing market demands, leading to a challenging environment for the industry [1] Financial Performance - The average revenue of vaccine companies in 2024 is 7.131 billion yuan, down 21.63% from 9.099 billion yuan in 2023, while the average net profit is 788 million yuan, a decrease of 35.60% from 1.222 billion yuan in 2023 [1] - Companies like Zhifei Biological, Wantai Biological, and Hualan Biological reported revenue declines exceeding 50%, while Watson Biological, Baike Biological, and Jindike saw declines of over 30% [1] - Kangxino's revenue increased by over 130% due to its quadrivalent meningococcal conjugate vaccine, benefiting from the resolution of global public health events [1] Price Competition Impact - The price war among vaccine products, particularly HPV, influenza, and pneumonia vaccines, has severely impacted net profits, with Wantai Biological, Kangtai Biological, Hualan Biological, and Zhifei Biological experiencing declines of 91.49%, 76.59%, 76.10%, and 74.99% respectively [2] - Wantai Biological's revenue for 2024 is 2.245 billion yuan, down 59.25%, and its net profit is 106 million yuan, down 91.49% [6] - Watson Biological's revenue is 2.821 billion yuan, a decline of 31.41%, with a net profit of 142 million yuan, down 66.10% [6] Market Dynamics - The domestic vaccine market is becoming increasingly competitive, with many companies focusing on traditional products and facing challenges from product homogeneity and market saturation [3] - The overall vaccination rate in China is low, with only about 3% for influenza vaccines, indicating significant growth potential in the market despite current pressures [7] R&D and Innovation - Companies are increasing R&D investments, with Zhifei Biological investing 1.391 billion yuan in 2024, and several companies allocating over 20% of their revenue to R&D [8] - New vaccine technologies, including mRNA and DNA vaccines, are emerging, which could lead to breakthroughs in disease prevention and treatment [9] International Expansion - Many vaccine companies are pursuing international markets, with Kangxino and Baike Biological successfully exporting products to various countries [10][11] - Watson Biological reported overseas revenue of 570 million yuan in 2024, a year-on-year increase of approximately 98% [11] - The global human vaccine market is projected to grow significantly, with emerging markets providing opportunities for Chinese vaccine companies due to their competitive pricing [12][13]

中信证券股份有限公司 关于江苏金迪克生物技术股份有限公司 持续督导保荐总结报告书 | | | 一、发行人基本情况 | 公司名称 | 江苏金迪克生物技术股份有限公司 | | --- | --- | | 股票简称 | 金迪克 | | 证券代码 | 688670.SH | | 注册资本 | 12,320.00 万元人民币 | | 注册地址 | 泰州市郁金路 12 号 | | 办公地址 | 泰州市郁金路 12 号 | | 法定代表人 | 余军 | | 本次证券发行类型 | 首次公开发行股票 | | 本次证券上市时间 | 2021 年 8 月 2 日 | | 本次证券上市地点 | 上海证券交易所 | 二、本次发行情况概述 经中国证券监督管理委员会证监许可[2021]1877 号文核准，并经上海证券交 易所同意，公司于 2021 年 7 月 21 日向社会公众公开发行普通股（A 股）股票 2,200.00 万股，每股面值 1.00 元，发行价格为每股人民币 55.18 元。截至 2021 年 7 月 27 日，公司共募集资金 1,213,960,000.00 元，扣除发行费用 78,283,870.00 元， 募集资金净 ...

Core Viewpoint - The price war in the influenza vaccine market has significantly impacted the financial performance of Jindike, leading to a substantial decline in revenue and profitability for the second consecutive year [1][5]. Financial Performance - In 2024, Jindike reported operating revenue of 80.8027 million yuan, a year-on-year decrease of 39.96%, resulting in a net loss of 93.5028 million yuan [2][6]. - The company has experienced a continuous decline in performance, with losses reported for three consecutive years from 2021 to 2023 [6]. - The price reduction of the four-valent influenza vaccine has contributed to the company's financial struggles, with the average price dropping from 128 yuan to 88 yuan, a decrease of 31.25% [6][7]. Product and Sales Performance - Jindike's only marketed product is the four-valent influenza virus split vaccine, which saw a 30% price reduction in 2024, leading to a significant compression of profit margins [3][8]. - The sales volume of the four-valent influenza vaccine was 1.1697 million doses in 2024, a year-on-year decrease of 15.32% [9]. - The company's gross margin for the four-valent influenza vaccine was 62.61% in 2024, down 15.2 percentage points from the previous year [8]. R&D and Future Plans - To reduce reliance on a single product, Jindike has increased its R&D investment, which accounted for 51.81% of its revenue in 2024, totaling approximately 41.8629 million yuan [12][13]. - The company is focusing on the development of a rabies vaccine, which has completed Phase III clinical trials and is currently undergoing product registration [4][15]. - Jindike is also expanding its product pipeline to include vaccines for chickenpox, shingles, and pneumococcal diseases, with ongoing clinical trials for its pediatric four-valent influenza vaccine [16].

Financial Performance - In 2024, the company reported operating revenue of 80.80 million yuan, a year-on-year decrease of 39.96% [1] - The net profit attributable to shareholders was -93.50 million yuan, compared to -70.99 million yuan in the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -106 million yuan, down from -72.57 million yuan year-on-year [1] - The net cash flow from operating activities was -131 million yuan, compared to 80.90 million yuan in the previous year [1] - For Q1 2025, the company achieved operating revenue of 3.46 million yuan, a decrease of 30.97% year-on-year [1] - The net profit attributable to shareholders for Q1 2025 was -17.58 million yuan, compared to -21.49 million yuan in the same period last year [1] - The net cash flow from operating activities for Q1 2025 was -42.06 million yuan, compared to -45.35 million yuan in the previous year [1] Dividend Policy - The company plans not to distribute profits for the 2024 fiscal year, with no cash dividends, capital reserve transfers, or stock bonuses [1] IPO and Fundraising - The company was listed on the Sci-Tech Innovation Board on August 2, 2021, with an initial public offering of 22 million shares at a price of 55.18 yuan per share [2] - The total amount raised from the IPO was 1.214 billion yuan, with a net amount of 1.136 billion yuan, which was 464 million yuan less than the originally planned net amount [2] - The company initially aimed to raise 1.6 billion yuan for various projects, including the construction of a new vaccine production facility and research and development [2] - The total issuance costs for the IPO were 78.28 million yuan, with the underwriter, CITIC Securities, receiving 64.34 million yuan in fees [2]